Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.

ABSTRACT:

Background

Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of chemotherapy are desirable. Poly-ADP-Ribose Polymerase inhibitors (PARPi) have shown to increase the activity of DNA damaging chemotherapeutics used in the treatment of CRC, however previous clinical trials failed to validate these results and pointed out dose-limiting toxicities that hamper the use of such combinations in unselected CRC patients. Nevertheless, in these studies little attention was paid to the mutational status of homologous recombination repair (HRR) genes.

Methods

We tested the combination of the PARPi niraparib with either 5-fluorouracil, oxalipla

SUBMITTER: Vitiello PP 

PROVIDER: S-EPMC7789007 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature